Skip to content

ASCOLABO

Active
Private limited companyfounded 200916 yrs activeKattestraat 19, 9300 Aalst, BelgiumKBO/BCE: BE 0819.241.214
Summary

ASCOLABO has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.2m and a net result of €241,033. Equity is growing by ~15.1% per year across the filed fiscal years. Its solvency ranks better than 57% of 19338 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).

Risk analysisWatch ReportCompare
ASCOLABOActiveChecked score 93/100
Risk analysis ReportCompare

Overview

Activity
Medical imaging and medical laboratories
NACE 86910NACE 86901
1 site
Size
€1.8mtotal assets 2025
Equity
€1.2m
Profit
€241,033
Turnover not published (abridged schema)
Financial health
93 Excellent Checked score 2025
Bankruptcy chance 12 m
< 0.1%
Structure
Board
3 members
Accounts 18 d early1 of 3 deeds read
Why 93- Liquidity: current ratio 0.52, cash €45,366+ Sector Human health activities (NACE 86)+ Size: total assets €1.8m+ Figures for FY 2025 (filed 13-01-2026)Show the evidence

Checked score

Score 2025
93 / 100
Excellent
Probability in this band: under 0.55%
Better than 40% of its sector peers (NACE 86, micro)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Strong
Solvency 95=
equity 70.0% of total assets
Liquidity 41-1
short-term debt 29.7% · cash 2.6%
Profitability 86+5
return on assets 13.7%
Bankruptcy probability, 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (23,682 companies)
Last 24 months 11-2024: < 0.1%lowest value 12-2024: < 0.1%▲ +10.5% vs 11-2024 01-2025: < 0.1%▲ +57.1% vs 12-2024 02-2025: < 0.1%● 0.0% vs 01-2025 03-2025: < 0.1%● 0.0% vs 02-2025 04-2025: < 0.1%● 0.0% vs 03-2025 05-2025: < 0.1%● 0.0% vs 04-2025 06-2025: < 0.1%● 0.0% vs 05-2025 07-2025: < 0.1%● 0.0% vs 06-2025 08-2025: < 0.1%▲ +3.0% vs 07-2025 09-2025: < 0.1%▲ +5.9% vs 08-2025 10-2025: < 0.1%▲ +2.8% vs 09-2025 11-2025: < 0.1%▲ +2.7% vs 10-2025 12-2025: < 0.1%▲ +2.6% vs 11-2025 01-2026: 0.1%▲ +30.8% vs 12-2025highest value 02-2026: < 0.1%▼ -39.2% vs 01-2026 03-2026: < 0.1%● 0.0% vs 02-2026 04-2026: < 0.1%● 0.0% vs 03-2026 05-2026: < 0.1%● 0.0% vs 04-2026 06-2026: < 0.1%▲ +3.2% vs 05-2026 07-2026: < 0.1%● 0.0% vs 06-2026 08-2026: < 0.1%▲ +3.1% vs 07-2026 09-2026: < 0.1%▲ +6.1% vs 08-2026 10-2026: < 0.1%▲ +5.7% vs 09-2026
  • Sector Human health activities (NACE 86) lowers the probability
  • Size: total assets €1.8m lowers the probability for this profile
  • Figures for FY 2025 (filed 13-01-2026) lowers the probability
  • Liquidity: current ratio 0.52, cash €45,366 raises the probability
Credit up to €110,000 at 30 days acceptable
Liquidity short (current ratio 0.52 against 1.07 in 2024; short-term debt: 29.7% and cash: 2.6% of total assets), and 30% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 86, micro). Better than this share of them on solvency 58%, liquidity 10%, profitability 37%, growth against the median 56%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Sector Human health activities (NACE 86)
In the bankruptcy model this factor lowers the probability.
KBO
lowers risk · Size: total assets €1.8m
In the bankruptcy model this factor lowers the probability for this profile.
NBB · annual accounts
lowers risk · Figures for FY 2025 (filed 13-01-2026)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Liquidity: current ratio 0.52, cash €45,366
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 13-01-2026, 18 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
18 d early
2024
49 d early
2023
8 d early
2022
1 d early
2021
49 d early
2020
10 d late
2019
18 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 19 days before the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today. Usually files around 13 January (5 of the last 5 filed years within 31 days of that day).
Companies Code · seven months
Position in the running window
30-06-2026 close03-10-2026 today31-01-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Appointments: Raepsaet Bruno, Leonard Raepsaet and…Power of attorney
  2. Annual accounts filedfiscal year 2025 · micro…
  3. Annual accounts filedfiscal year 2024 · micro…

Key points

  • Positive: Among the best 5% on equitysector median €127,624 · 19,341 companies €1.2m View
  • Positive: Result rose in 2025from €157,024 to €241,033 ▲ 53.5% View
  • New directorslatest change 21-09-2026 · 3 in office 3 joined View
  • Positive: 7 profitable years in a rowprofit 2025: €241,033 7 years View
  • Positive: Always filed on timeaccounts within the deadline every year 5 years View

By topic

Financials

Fiscal year
2025
Total assets
€1.8m
Profit
€241,033
Solvency
70.0%
Total assets▲ 13.2%
Net result
20192025
Go to Financials

Timeline

Events
14
Since
2017
Next accounts
by 31-01-2027
  1. 21-09-2026Appointments: Raepsaet Bruno, Leonard Raepsaet and Gaëlle…
  2. 13-01-2026Annual accounts filed
  3. 13-12-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Medical imaging and medical laboratoriesNACE 86910
Founded
05-10-2009
Year ends
30-06
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure